Zacks Analyst Blog Highlights: Hasbro, Mattel, Medivation Inc., Pfizer and Raser Technologies

Chicago, IL – June 30, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Hasbro (HAS), Mattel (MAT), Medivation Inc. (MDVN), Pfizer (PFE) and Raser Technologies (RZ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

Hasbro Scores With Transformers

The extremely strong opening delivered by the Transformers movie sequel could bode well for Hasbro’s (HAS) sales in the coming months.

The film, Transformers: Revenge of the Fallen, racked up domestic ticket sales of more than $200 million in the 5 days since its opening on Wednesday. This financial performance exceeded expectations, and narrowly missed setting the record for 5-day revenues set last year by the Batman sequel, The Dark Knight.

Owning the brand upon which the movie is based provides Hasbro with several benefits that could give it an advantage relative to peers such as Mattel (MAT).

Medivation - Dimebon Launch in 2012?

Medivation Inc. (MDVN) reported first quarter 2009 financial results following the market close on May 11, 2009. Revenue came in at $16.34 million, exactly where we had it modeled. Revenue consisted solely of collaboration revenue from Pfizer (PFE). EPS was ($0.19), significantly ahead of our forecast of ($0.34), due to substantially lower-than-expected operating expenses.

Pfizer makes quarterly true-up payments to Medivation as reimbursement for a significant portion of Dimebon-related development and commercialization expenses. In the first quarter 2009, Pfizer made a $5.8 million true-up payment to MDVN, which is reflected as a reduction in operating expenses – approximately $5.4 million of the true-up payment hit the R&D expense line-item.

Raser Technologies (RZ) Update

Raser Technologies (RZ) is gradually transforming itself from a developmental stage company to an operating geothermal power producer, although not a "pure play".

Looking forward, this yet to break-even company will likely transform its barren financials through the commencement of production at its first geothermal plant in Utah, purchased power agreements (PPAs), turbine deliveries, extension of the production tax credit (PTC), in addition to Symetron's progress in its SUV demonstration vehicle and heavy duty alternators.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/ZacksInvestment

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Read the full analyst report on HAS

Read the full analyst report on MAT

Read the full analyst report on MDVN

Read the full analyst report on PFE

Read the full analyst report on RZ